Zealand Pharma Statistics

Total Valuation

Zealand Pharma has a market cap or net worth of DKK 26.17 billion. The enterprise value is 18.02 billion.

Market Cap	26.17B
Enterprise Value	18.02B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Zealand Pharma has 70.99 million shares outstanding. The number of shares has increased by 16.16% in one year.

Current Share Class	70.99M
Shares Outstanding	70.99M
Shares Change (YoY)	+16.16%
Shares Change (QoQ)	-0.20%
Owned by Insiders (%)	0.32%
Owned by Institutions (%)	53.68%
Float	60.75M

Valuation Ratios

PE Ratio	n/a
Forward PE	4.81
PS Ratio	469.81
PB Ratio	3.15
P/TBV Ratio	3.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-15.20
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.76

Financial Position

The company has a current ratio of 25.10, with a Debt / Equity ratio of 0.05.

Current Ratio	25.10
Quick Ratio	24.39
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.32
Interest Coverage	-40.02

Financial Efficiency

Return on equity (ROE) is -21.27% and return on invested capital (ROIC) is -14.88%.

Return on Equity (ROE)	-21.27%
Return on Assets (ROA)	-13.97%
Return on Invested Capital (ROIC)	-14.88%
Return on Capital Employed (ROCE)	-16.20%
Revenue Per Employee	144,660
Profits Per Employee	-3.08M
Employee Count	335
Asset Turnover	0.01
Inventory Turnover	0.03

Taxes

Income Tax	-4.64M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.17% in the last 52 weeks. The beta is 0.56, so Zealand Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.56
52-Week Price Change	-51.17%
50-Day Moving Average	431.47
200-Day Moving Average	661.23
Relative Strength Index (RSI)	35.54
Average Volume (20 Days)	786,831

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zealand Pharma had revenue of DKK 55.69 million and -1.19 billion in losses. Loss per share was -17.26.

Revenue	55.69M
Gross Profit	52.01M
Operating Income	-1.42B
Pretax Income	-1.19B
Net Income	-1.19B
EBITDA	-1.41B
EBIT	-1.42B
Loss Per Share	-17.26

Full Income Statement

Balance Sheet

The company has 8.54 billion in cash and 394.64 million in debt, giving a net cash position of 8.15 billion or 114.81 per share.

Cash & Cash Equivalents	8.54B
Total Debt	394.64M
Net Cash	8.15B
Net Cash Per Share	114.81
Equity (Book Value)	8.31B
Book Value Per Share	117.53
Working Capital	8.60B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.21 billion and capital expenditures -12.98 million, giving a free cash flow of -1.22 billion.

Operating Cash Flow	-1.21B
Capital Expenditures	-12.98M
Free Cash Flow	-1.22B
FCF Per Share	-17.20

Full Cash Flow Statement

Margins

Gross Margin	93.39%
Operating Margin	-2,550.13%
Pretax Margin	-2,136.97%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Zealand Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.16%
Shareholder Yield	n/a
Earnings Yield	-4.53%
FCF Yield	-4.67%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zealand Pharma has an Altman Z-Score of 37.79 and a Piotroski F-Score of 1.

Altman Z-Score	37.79
Piotroski F-Score	1